This is a review of the recent STARGLO 2-years follow-up: Glofitamab-GemOx versus rituximab-GemOx for relapsed/refractory diffuse LBCL.
Independent commentary has been provided by Dr Adrian Minson, a haematologist and clinician researcher at the Peter MacCallum Cancer Centre/Royal Melbourne Hospital and Cabrini Health.
Please login below to download this issue (PDF)